StreetInsider

• Log in to your account:

  
  Log in
• Signup
• Home
• EPS Insider
• Event Calendar
• Conferences
• Classic Site

Upgrade to SI Premium - Free Trial

INmune Bio (INMB)

INmune Bio files for EMA orphan drug status for its RDEB cell therapy August 26, 2026 7:02 AM - StreetInsider INmune Bio Advances Ebstrocel™ Toward European Marketing Authorization with EMA Regulatory Filings August 26, 2026 7:00 AM - StreetInsider INmune Bio, Inc. (INMB) Tops Q2 EPS by 14c August 6, 2026 5:38 PM - StreetInsider Form 10-Q Inmune Bio, Inc. For: Jun 30 August 6, 2026 4:10 PM - SEC Filing INmune Bio Inc. Announces Second Quarter 2026 Results and Highlights Regulatory, Manufacturing and Clinical Progress August 6, 2026 4:00 PM - StreetInsider Form 8-K Inmune Bio, Inc. For: Jul 31 July 31, 2026 4:06 PM - SEC Filing INmune Bio receives $4.6M in R&D rebates from UK and Australia July 31, 2026 7:00 AM - StreetInsider INmune Bio Receives R&D Rebates of Approximately $4.6 Million July 31, 2026 7:00 AM - Globe NewsWire INmune Bio Inc. to Report Second Quarter 2026 Financial Results and Provide Corporate Update on Thursday, August 6th July 31, 2026 7:00 AM - StreetInsider INmune Bio Receives R&D Rebates of Approximately $4.6 Million July 31, 2026 7:00 AM - StreetInsider INmune Bio forms advisory board for CORDStrom cell therapy platform July 30, 2026 7:00 AM - StreetInsider INmune Bio Establishes Scientific Advisory Board to Support Late-Stage Development and Expansion of CORDStrom™ Platform July 30, 2026 7:00 AM - StreetInsider INmune Bio Completes Commercial Manufacturing Milestone Supporting Planned Global Registration Filings for CORDStrom™ Platform July 20, 2026 7:00 AM - StreetInsider INmune Bio publishes preclinical study on XPro1595 and brain injury July 15, 2026 7:01 AM - StreetInsider INmune Bio’s XPro1595 Prevents Brain-Injury-Induced Alzheimer's Pathology, Memory Loss, and Pain in New Peer-Reviewed Preclinical Study July 15, 2026 7:00 AM - Globe NewsWire INmune Bio’s XPro1595 Prevents Brain-Injury-Induced Alzheimer's Pathology, Memory Loss, and Pain in New Peer-Reviewed Preclinical Study July 15, 2026 7:00 AM - StreetInsider INmune Bio to present Phase 2 imaging data for XPro at AAIC 2026 July 9, 2026 7:00 AM - StreetInsider INmune Bio to Present Positive Phase 2 Imaging Data for XPro in Early Alzheimer’s Disease at AAIC July 9, 2026 7:00 AM - StreetInsider Form 4 Inmune Bio, Inc. For: Jul 02 Filed by: Juda Scott July 7, 2026 7:02 AM - SEC Filing Form 4 Inmune Bio, Inc. For: Jul 02 Filed by: Lowdell Mark William July 7, 2026 7:01 AM - SEC Filing Form 4 Inmune Bio, Inc. For: Jul 02 Filed by: Moss David J July 7, 2026 7:00 AM - SEC Filing Form 8-K Inmune Bio, Inc. For: Jun 30 July 1, 2026 7:16 AM - SEC Filing INmune Bio files CORDStrom patent in U.S. after favorable PCT opinion July 1, 2026 7:02 AM - StreetInsider INmune Bio Advances CORDStrom™ Platform Patent Application in the U.S. Following Favorable International Written Opinion July 1, 2026 7:00 AM - StreetInsider INmune Bio receives MHRA pediatric plan approval for Ebstrocel June 25, 2026 7:00 AM - StreetInsider INmune Bio Inc. Achieves MHRA Approval of PIP for CORDStrom™ June 25, 2026 7:00 AM - StreetInsider Form 8-K Inmune Bio, Inc. For: Jun 23 June 23, 2026 4:06 PM - SEC Filing INmune Bio gets MHRA alignment for 2026 UK drug application June 23, 2026 8:03 AM - StreetInsider INmune Bio Receives MHRA Written Alignment Supporting Planned 2026 UK Conditional Marketing Authorization Application for CORDStrom™ in RDEB June 23, 2026 8:00 AM - StreetInsider Form 8-K Inmune Bio, Inc. For: Jun 16 June 17, 2026 4:01 PM - SEC Filing Full Article List